Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07631572 · ClinicalTrials.gov registry record · NA

Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer

A NA study, sponsored by Denise Fabian.

Recruiting
Registry status
NA
Development phase
10
Enrollment target

NCT07631572 is a NA study that is actively recruiting participants, run by Denise Fabian. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07631572, a NA study, is actively recruiting participants, sponsored by Denise Fabian.

RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target

Study Summary

This clinical trial studies how well cesium-131 low-dose rate interstitial brachytherapy works as an organ-preserving radiation technique in the treatment of patients with cervical and endometrial cancer that has come back in the vagina after a period of improvement following pelvic radiation therapy (vaginal recurrence). In cervical and endometrial cancer patients with vaginal recurrence following pelvic radiation therapy, the only curative option involves a major surgical procedure which removes all the contents of the pelvic cavity, such as the uterus, cervix, bladder, rectum, vagina, and vulva. This procedure is complex and comes with many side effects; therefore, a need remains to improve radiation treatment techniques so radiation therapy can be offered as an alternative treatment option for these patients. Cesium-131 low-dose rate interstitial brachytherapy is a form of internal radiation therapy called brachytherapy. It uses grain-of-rice-sized radioactive seeds implanted directly into or near where the tumor has returned. The implanted seeds give off radiation to kill tumor cells for only a short time after they are placed. Most of the radiation is gone within a few weeks. The seeds stay in the body permanently, but they become inactive quickly. Cesium-131 low-dose rate interstitial brachytherapy may be an effective organ-preserving radiation technique for the treatment of cervical and endometrial cancer patients with vaginal recurrence following pelvic radiation therapy

Interventions

  • DEVICE Cesium-131 Low Dose Radiation (LDR)

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2026-07
Est. Completion 2030-05
Phase NA

Sponsor

Denise Fabian

3 total trials

What the Registry Record Tells You About NCT07631572

The ClinicalTrials.gov registry entry for NCT07631572 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denise Fabian, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Cesium-131 Low Dose Radiation (LDR) is the first listed.

NCT07631572 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07631572 about?

NCT07631572 is a clinical study titled "Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer". This clinical trial studies how well cesium-131 low-dose rate interstitial brachytherapy works as an organ-preserving radiation technique in the treatment of patients with cervical and endometrial cancer that has come back in the vagina after a period of improvement following pelvic radiation therap...

What is the current status of trial NCT07631572?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-07. Estimated completion is 2030-05.

What interventions are being tested in trial NCT07631572?

The interventions under investigation include: Cesium-131 Low Dose Radiation (LDR) (DEVICE).

Who is sponsoring clinical trial NCT07631572?

This trial is sponsored by Denise Fabian, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.